Proceedings from a Clinical Dermatology Roundtable. Supplement to the March 2010 issue of The Journal of Clinical and Aesthetic Dermatology

This supplement was supported by Pharmaderm, a division of Nycomed US Inc.

Click hyperlink below to access supplement:

Diclofenac Sodium 3% Gel for the Treatment of Actinic Keratosis: Case-based Experience –

Mary S. Brady, MD; Memorial Sloan-Kettering Cancer Center, New York, New York; Nikki S. Noce, New York University Medical Center, New York, New York

Disclosure: The authors report no relevant conflicts of interest. Read the rest of this article »

Mark S. Nestor, MD, PhD, Center for Clinical and Cosmetic Research, Aventura, Florida; Glynis R. Ablon, MD, Ablon Skin Institute, Manhattan Beach, California; Mark A. Stillman, PhD, Center for Clinical and Cosmetic Research, Aventura, Florida

Disclosure: Dr. Nestor has received research grant support from and is a consultant and speaker for Medicis. Dr. Ablon has been a consultant for Medicis. Dr. Stillman reports no relevant conflicts of interest. This study was funded by an unrestricted educational grant from ThermoTek. The product used in this study was supplied by Medicis Aesthetics Incorporated. Read the rest of this article »

Ashley Collins, MD; Department of Biochemistry, North Carolina State University; Adnan Nasir, MD, Department of Dermatology, University of North Carolina, Chapel Hill, North Carolina

Abstract
Nanotechnology is a rapidly growing discipline that capitalizes on the unique properties of matter engineered on the nanoscale. Vehicles incorporating nanotechnology have led to great strides in drug delivery, allowing for increased active ingredient stability, bioavailability, and site-specific targeting. Botulinum toxin has historically been used for the correction of neurological and neuromuscular disorders, such as torticollis, blepharospasm, and strabismus. Recent dermatological indications have been for the management of axillary hyperhydrosis and facial rhytides. Traditional methods of botulinum toxin delivery have been needle-based. These have been associated with increased pain and cost. Newer methods of botulinum toxin formulation have yielded topical preparations that are bioactive in small pilot clinical studies. While there are some risks associated with topical delivery, the refinement and standardization of delivery systems and techniques for the topical administration of botulinum toxin using nanotechnology is anticipated in the near future.  (J Clin Aesthetic Dermatol. 2010;3(3):35–39.) Read the rest of this article »

Gao Yang, MD, Laser Center, Jinshan Hospital, Fudan University, Shanghai, China; Leihong Flora Xiang, MD, PhD Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China; Michael H. Gold, MD, Gold Skin Care Center, Tennessee Clinical Research Center, Nashville, Tennesee; Vanderbilt University School of Medicine, Department of Dermatology; Vanderbilt University School of Medicine, School of Nursing, Nashville, Tennesee; Huashan Hospital, Fudan University, Shanghai, China; Number One Hospital, China Medical University, Shenyang, China Read the rest of this article »

Morgan McCarty (MS4);
James Q. Del Rosso, DO, FAOCD

Section Editor: James Q. Del Rosso, DO, FAOCD

Ms. McCarty (MS4) is from Midwestern University AZCOM, Glendale, Arizona. Dr. Del Rosso is Dermatology Residency Director, Valley Hospital Medical Center, Las Vegas, Nevada. Disclosure: Ms. McCarty and Dr. Del Rosso report no relevant conflicts of interest. Read the rest of this article »